Amneal names 3 executives to its board of directors
Jeff George, John Kiely and Shlomo Yanai have been appointed to Amneal's board of directors, effective Dec. 14, 2019.
“It is a testament to the opportunities ahead for Amneal that we have attracted leaders of Jeff, John and Shlomo’s caliber to our board. They each have deep knowledge of our industry, and we are confident they will help us capitalize on those opportunities. Moving forward, we will continue to add new expertise and fresh perspectives to our board,” said Paul Meister, chairman of Amneal’s board.
“Jeff, John and Shlomo each bring tremendous records of leadership and delivering results in the global pharmaceutical and healthcare industries, and we are pleased to welcome them to the Amneal board. We look forward to working closely with them as we execute on our strategies to reinvigorate Amneal, drive growth and create value for patients, shareholders and our other stakeholders,” said Amneal co-founders and co-CEOs, Chirag Patel and Chintu Patel.
George has nearly 20 years of global healthcare and corporate leadership experience across North America, Europe and emerging markets. He currently serves as managing partner of Maytal Capital, a private equity investment and advisory firm he founded, as well as an operating partner at Revival Healthcare Capital, a medical-device private equity firm.
He previously served as division head and CEO of Sandoz, from 2008 to 2014; as division head and CEO of Alcon, from 2014 to 2016; and more recently as CEO and board member of Performance Health. He currently serves on the board of Silicon Valley-based healthcare software firm Roam Analytics and previously served on the boards of AdvaMed (the Advanced Medical Technology Association) and Performance Health Holdings.
Kiely has more than 35 years of financial leadership and advisory experience serving public companies, including multi-national corporations. Until June 2019 he served as senior assurance partner at Pricewaterhouse Coopers, where he focused on the pharmaceutical, manufacturing chemical and medical device sectors. Since 1980, he has held various roles of increasing responsibility at Pricewaterhouse Coopers, including as U.S. pharmaceutical leader and global pharmaceutical assurance leader. Kiely currently serves on the board at Zovio.
Yanai has more than 15 years of corporate leadership experience, primarily in the pharmaceutical industry. He most recently served as president and CEO at Teva, from 2007 to 2012.
Yanai also serves as an advisor to CVC Capital Partners, a leading private equity firm with $80.5 billion in assets under management. In addition, he currently serves on the boards of PDL BioPharma and WR Grace & Co. Yanai previously served on the boards of Cambrex, Lumenis, Perrigo and Sageant Pharmaceuticals, among others, and held various leadership positions in the Israel Defense Forces.
Amneal also announced that Jean Selden Greene has retired from the Amneal board, effective as of Dec.14, 2019. The company said that Greene's resignation was not based on any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. As a result of the foregoing changes on board composition, the board will comprise eleven directors.